These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21356651)

  • 1. Noninfectious pneumonitis in a patient with renal cell carcinoma treated with everolimus.
    Creel P; Moldawer NP
    Oncol Nurs Forum; 2011 Mar; 38(2):125-8. PubMed ID: 21356651
    [No Abstract]   [Full Text] [Related]  

  • 2. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma.
    White DA; Camus P; Endo M; Escudier B; Calvo E; Akaza H; Uemura H; Kpamegan E; Kay A; Robson M; Ravaud A; Motzer RJ
    Am J Respir Crit Care Med; 2010 Aug; 182(3):396-403. PubMed ID: 20194812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma.
    Saito Y; Nagayama M; Miura Y; Ogushi S; Suzuki Y; Noro R; Minegishi Y; Kimura G; Kondo Y; Gemma A
    Jpn J Clin Oncol; 2013 May; 43(5):559-62. PubMed ID: 23423809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of mTOR inhibitor side effects.
    Creel PA
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New mTOR inhibitor for renal cell cancer.
    Wilkes GM
    Oncology (Williston Park); 2009 Jul; 23(8 Suppl):54-6. PubMed ID: 19860046
    [No Abstract]   [Full Text] [Related]  

  • 6. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pneumonitis caused by sirolimus: improvement after switching to everolimus].
    Calle L; Tejada C; Lancho C; Mazuecos A
    Nefrologia; 2009; 29(5):490-1. PubMed ID: 19820768
    [No Abstract]   [Full Text] [Related]  

  • 8. Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
    Rehm B; Keller F; Mayer J; Stracke S
    Transplant Proc; 2006 Apr; 38(3):711-3. PubMed ID: 16647451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.
    Rodríguez-Moreno A; Ridao N; García-Ledesma P; Calvo N; Pérez-Flores I; Marques M; Barrientos A; Sánchez-Fructuoso AI
    Transplant Proc; 2009; 41(6):2163-5. PubMed ID: 19715862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
    van den Eertwegh AJ; Karakiewicz P; Bavbek S; Rha SY; Bracarda S; Bahl A; Ou YC; Kim D; Panneerselvam A; Anak O; Grünwald V
    Urology; 2013 Jan; 81(1):143-9. PubMed ID: 23273080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the diffusion capacity for carbon monoxide and the development of non-infectious pneumonitis in patients with metastatic renal cell carcinoma treated with everolimus.
    Park K; Kim HJ; Lee JL; Lee KH; Jeong IG; Song C; Hong BS; Hong J; Kim CS; Ahn H
    Anticancer Res; 2014 Oct; 34(10):5723-8. PubMed ID: 25275080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin (mTOR)-related non-infectious pneumonitis: a potential biomarker of clinical benefit?
    Rodriguez-Vida A; Chau NM; Chowdhury S
    BJU Int; 2014 Mar; 113(3):350-1. PubMed ID: 24528875
    [No Abstract]   [Full Text] [Related]  

  • 14. Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report.
    De Simone P; Petruccelli S; Precisi A; Carrai P; Doria R; Menichetti F; Filipponi F
    Transplant Proc; 2007 Dec; 39(10):3500-1. PubMed ID: 18089420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal case of cryptogenic organizing pneumonia associated with everolimus.
    Nazer L; Alnajjar T; Salah S; Khzouz J; Alfaqeer N; Qandeel M
    Ann Saudi Med; 2014; 34(5):437-9. PubMed ID: 25827702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
    Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options.
    Schrader J; Sterneck M; Klose H; Lohse AW; Nashan B; Fischer L
    Transpl Int; 2010 Jan; 23(1):110-3. PubMed ID: 19497063
    [No Abstract]   [Full Text] [Related]  

  • 18. Lingual angioedema associated with everolimus.
    Mackenzie M; Wood LA
    Acta Oncol; 2010; 49(1):107-9. PubMed ID: 20100146
    [No Abstract]   [Full Text] [Related]  

  • 19. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.
    Seidel C; Fenner M; Reuter C; Merseburger AS; Ganser A; Grünwald V
    Onkologie; 2011; 34(3):111-4. PubMed ID: 21358215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib.
    Ruangkanchanasetr P; Kanjanapayak B; Jungmeechoke K
    Nephrology (Carlton); 2011 Jan; 16(1):118-9. PubMed ID: 21175989
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.